Agoraphobia Test: A Clinician’s Guide to Recognising Agoraphobia, the Symptoms, the Self-Assessment Questions, the Difference From Social Anxiety and Panic Disorder, and the Hidden Role of Alcohol

A clinician’s guide to agoraphobia, the symptoms to recognise, a structured self-assessment that mirrors the questions clinicians use, the difference between agoraphobia and social anxiety disorder or panic disorder, the impact on physical health and mental health, the treatment options including cognitive behavioural therapy and medications, and the often-overlooked alcohol use that develops alongside the avoidance pattern.

Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.

Agoraphobia is the anxiety disorder defined by fear of situations from which escape might be difficult or in which help might not be available if a panic attack or other distressing symptoms occurred. The DSM-5 criteria require marked fear or anxiety about at least two of five situational clusters: public transportation, open spaces, enclosed spaces, standing in line or being in a crowd, and being outside of the home alone. People with agoraphobia avoid these situations, endure them only with intense anxiety, or require a companion. The fear is persistent (typically 6 months or more), causes substantial distress or functional impairment, and is out of proportion to the actual danger of the situations. A simple self-assessment with five questions about avoidance of these situations can identify whether agoraphobia may be present and whether formal evaluation is appropriate. Agoraphobia commonly co-occurs with panic disorder and with depression, and the alcohol use that often develops as people try to manage the anxiety can itself become a clinical problem. Treatment includes cognitive behavioural therapy with structured exposure, antidepressant medications (SSRIs and SNRIs), and integrated care for any co-occurring substance use disorder. The condition is highly treatable when properly diagnosed and addressed.

What is agoraphobia?

Agoraphobia is the anxiety disorder defined by fear of situations from which escape might be difficult or in which help might not be available if a panic attack, other incapacitating symptoms, or embarrassing symptoms occurred. The term derives from the Greek agora (marketplace) and phobos (fear), and historically referred specifically to fear of open public spaces. The current DSM-5 definition is broader and includes a range of situations united by the theme of being away from a safe place or person.

The DSM-5 diagnostic criteria require marked fear or anxiety about at least two of five situational clusters: using public transportation (buses, trains, planes, ships), being in open spaces (parking lots, marketplaces, bridges), being in enclosed places (shops, theatres, cinemas), standing in line or being in a crowd, and being outside of the home alone. The fear must be persistent, typically for six months or more; the situations must be actively avoided, require a companion, or be endured with intense fear or anxiety; the fear must be out of proportion to the actual danger; and the condition must cause substantial distress or functional impairment in important areas of life.

Agoraphobia exists on a spectrum of severity. Mild agoraphobia may involve occasional avoidance of specific high-anxiety situations (long-distance flights, large crowds) with normal functioning otherwise. Moderate agoraphobia substantially restricts the person’s life, with regular avoidance of routine activities (grocery shopping, driving on highways, attending events) and considerable distress when the situations cannot be avoided. Severe agoraphobia can leave the person homebound, unable to leave their residence without intense panic, dependent on family members for activities of daily living, and substantially socially isolated. The most severe presentations are now relatively uncommon because of better treatment availability but were a defining feature of agoraphobia in earlier eras.

Agoraphobia is one of the more common anxiety disorders. Lifetime prevalence is estimated at 1.3 percent in the United States and similar in other Western countries. The condition typically develops in adolescence or young adulthood, with peak onset between ages 15 and 35, although later onset can occur. Women are diagnosed at roughly twice the rate of men, possibly because of true sex differences in the disorder or possibly because of differences in help-seeking and diagnostic practice. Family history of anxiety disorders raises the risk; specific genetic variants have been associated but no single gene explains a substantial fraction of cases.

Agoraphobia self-assessment test

A structured self-assessment can help identify whether agoraphobia may be present and whether formal evaluation is appropriate. The questions below mirror the DSM-5 criteria and the questions clinicians use during evaluation. A score of 2 or more positive answers among the first five questions, combined with substantial distress or functional impairment, suggests agoraphobia may be present and warrants clinical assessment. The self-assessment is not a substitute for clinical evaluation but is a useful first step.

Question 1: Do you experience marked fear or anxiety about using public transportation, including buses, trains, planes, or ships? Consider whether you avoid these situations, require a companion, or endure them only with substantial distress. Yes or no.

Question 2: Do you experience marked fear or anxiety about being in open spaces such as parking lots, marketplaces, bridges, or open countryside? Consider whether the size of the open space, the distance from buildings, or the lack of clear escape routes contributes to the anxiety. Yes or no.

Question 3: Do you experience marked fear or anxiety about being in enclosed places such as shops, theatres, cinemas, lifts, or aircraft? Consider whether the enclosed space, the difficulty of leaving quickly, or the presence of other people in the enclosed space contributes to the anxiety. Yes or no.

Question 4: Do you experience marked fear or anxiety about standing in a line or being in a crowd? Consider whether the inability to leave easily, the proximity to other people, or the lack of personal space contributes to the anxiety. Yes or no.

Question 5: Do you experience marked fear or anxiety about being outside of the home alone? Consider whether you require a companion for activities outside the home, whether you avoid going out alone, or whether you endure being alone outside with substantial distress. Yes or no.

Question 6: Have these fears been present for six months or more? Question 7: Do the fears cause substantial distress or interfere with your work, social life, or important relationships? Question 8: Have you been actively avoiding the situations, requiring a companion for them, or enduring them only with intense anxiety? Question 9: Have you considered whether the fears might be related to a previous panic attack, or to the possibility of a future panic attack, embarrassing symptoms, or being unable to escape?

Symptoms of agoraphobia

Physical symptoms of agoraphobia include the standard anxiety symptoms when the person is in or anticipating the feared situations: racing or pounding heart (palpitations), sweating, trembling or shaking, shortness of breath, choking sensation, chest pain or discomfort, nausea or abdominal distress, dizziness or lightheadedness, chills or hot flushes, numbness or tingling, derealisation (feelings of unreality) or depersonalisation (feeling detached from oneself), fear of losing control or going crazy, and fear of dying. Many people experience these symptoms in the form of full panic attacks, particularly in the early stages of the condition. Anticipatory anxiety, which builds in the hours or days before a planned exposure to a feared situation, can be as distressing as the situation itself.

Cognitive symptoms include intrusive thoughts about the feared situations, persistent worry about future situations the person may have to face, catastrophic thinking about what would happen if a panic attack occurred in a particular place (the train would not stop, no one would help, the person would be embarrassed, they would faint or have a heart attack), and the broader sense that the world outside the safe zone is dangerous. The cognitive patterns reinforce the avoidance and contribute to the maintenance of the disorder over years.

Behavioural symptoms are the most visible part of the disorder. Active avoidance of the feared situations is the hallmark; the person rearranges their life to avoid public transportation, open spaces, enclosed places, crowds, or being alone outside the home. Safety behaviours develop alongside the avoidance: carrying anti-anxiety medication in case of a panic attack, always knowing where the exits are, sitting at the back of rooms near the door, going only to specific shops at specific times when they are not crowded, requiring a companion (often a specific person who has become a safe person) for any activity outside the safe zone. Many of these behaviours are subtle and the person may not recognise them as related to the disorder.

Emotional symptoms include the chronic anxiety that runs in the background even when the person is in safe places, the fear of fear (anxiety about future anxiety), frustration with themselves about the pattern, depression that often develops alongside or in response to the agoraphobia, and the loneliness of the social isolation that the avoidance produces over time. Many patients describe a sense that their world has shrunk over the years as the avoidance expanded and that they have lost relationships, opportunities, and experiences they would have wanted.

Functional impairment from agoraphobia can be substantial. Work limitations are common; people with agoraphobia may need to work from home, may avoid jobs that require commuting on public transportation or attending large meetings, or may be unable to work entirely. Relationship impacts include strain on family members who become the safe companion, social withdrawal from friends and activities outside the safe zone, and limitations on dating and forming new relationships. Physical health is affected by reduced activity, missed medical appointments because of fear of waiting rooms, and the broader sedentary pattern that often develops with severe agoraphobia.

Agoraphobia vs panic disorder vs social anxiety disorder

Agoraphobia, panic disorder, and social anxiety disorder are related but distinct anxiety conditions that often co-occur. Panic disorder is defined by recurrent unexpected panic attacks plus at least one month of persistent worry about additional panic attacks or significant maladaptive changes in behaviour related to the attacks. Many people with panic disorder also develop agoraphobia, traditionally in the form of avoiding situations where past panic attacks occurred or where escape would be difficult if an attack occurred. The DSM-5 separated the two conditions to clarify that agoraphobia can also exist without panic disorder, although in clinical practice they frequently co-occur.

Social anxiety disorder (formerly social phobia) is the fear of social or performance situations in which the person may be scrutinised by others. The core fear in social anxiety is judgment, embarrassment, or rejection by others. The fear in agoraphobia is being unable to escape or get help if something goes wrong, regardless of judgment by others. The two can overlap because many feared situations (crowded shops, public transportation, lines) involve both other people and potential for incapacitation. The clinical distinction matters because the treatment focus differs; social anxiety treatment addresses the fear of judgment, while agoraphobia treatment addresses the fear of being trapped or unable to get help.

Generalised anxiety disorder (GAD), specific phobias, post-traumatic stress disorder, and obsessive-compulsive disorder can also share some features with agoraphobia. Differentiating these conditions requires careful clinical evaluation. Many patients have features of more than one anxiety disorder, and treatment needs to address all the contributing patterns. Depression frequently co-occurs with agoraphobia and may require its own treatment alongside the anxiety work.

Substance use disorders, particularly alcohol use disorder, frequently co-occur with agoraphobia and panic disorder. The pattern is widespread: the patient uses alcohol to manage the anxiety, develops alcohol use disorder over time, and ends up with both conditions interacting. The alcohol both provides short-term relief and worsens the underlying anxiety over the longer term. Treatment of either condition without addressing the other often produces inadequate response. Integrated dual-diagnosis treatment is the standard of care.

Causes and contributors

The causes of agoraphobia are multifactorial. Genetic vulnerability contributes; first-degree relatives of people with agoraphobia have elevated rates of agoraphobia, panic disorder, and other anxiety conditions. Specific genetic variants have been associated in genome-wide studies but no single gene explains a substantial fraction of cases. The genetic contribution interacts with environmental factors throughout development.

A history of panic attacks is one of the strongest risk factors for agoraphobia. Many cases of agoraphobia begin with one or several unexpected panic attacks, often in a specific situation (a shopping mall, a crowded event, a long drive). The person then develops fear of returning to similar situations because of the possibility of another panic attack. The avoidance behaviour grows from this initial fear and gradually expands as the person experiences fewer panic attacks (because they are avoiding the trigger situations) but also fewer reality checks against the catastrophic predictions.

Stress and life events can precipitate agoraphobia in vulnerable individuals. Major life transitions (moving to a new city, starting a new job, ending a relationship), significant losses, medical illnesses, and other stressors can trigger the first panic attack or the first significant period of agoraphobia. Childhood adverse experiences (parental conflict, neglect, abuse, parental anxiety modelled in the home) raise the lifetime risk of anxiety disorders including agoraphobia. The specific environmental contributors vary widely between patients.

Behavioural and cognitive patterns maintain agoraphobia once it has developed. The avoidance behaviour is reinforcing because it produces immediate anxiety relief, which makes the person more likely to avoid in the future. The catastrophic thinking about what would happen in feared situations is never tested against reality because the avoidance prevents the test from happening. The safety behaviours (carrying medication, knowing exits, having a companion) prevent the person from learning that they could cope without these safety measures. The pattern self-maintains over years through these mechanisms even after the original triggers have faded.

Agoraphobia and alcohol: the under-recognised pattern

Heavy drinking combined with agoraphobia is one of the more common patterns in clinical practice. The mechanism is straightforward: the person with anxiety uses alcohol to manage the symptoms, and the alcohol provides genuine short-term relief. The pattern reinforces itself over time, with the person using alcohol before any potentially anxiety-provoking situation, drinking heavily in the evenings to wind down from the day’s accumulated anxiety, and developing increasing alcohol tolerance and dependence as the use becomes daily. The alcohol use becomes a clinical problem in its own right while the underlying agoraphobia continues.

The biochemistry of the alcohol-anxiety interaction explains why the pattern is so difficult to break. Alcohol acutely enhances GABA-A receptor function, producing the calming and disinhibiting effects that provide anxiety relief. Chronic heavy alcohol use produces compensatory changes (downregulation of GABA-A receptors, upregulation of glutamate NMDA receptors) that increase the underlying anxiety baseline when alcohol is not in the system. The person ends up with elevated baseline anxiety that is partially masked by ongoing drinking, and the agoraphobia symptoms become worse without the alcohol than they were before the alcohol use began.

Alcohol withdrawal itself produces significant anxiety symptoms that can mimic or worsen the agoraphobia picture. The patient who tries to reduce or stop drinking experiences anxiety, sweating, racing heart, and a sense of doom that closely resembles the panic symptoms they are trying to avoid. This often drives the patient back to drinking, which provides short-term relief but reinforces the cycle. Medical detox in a clinical setting may be necessary for patients with established physical dependence on alcohol to safely move toward treating both conditions.

The treatment approach for combined agoraphobia and alcohol use disorder requires addressing both conditions, ideally in an integrated way. Treating the alcohol use without addressing the underlying anxiety typically produces relapse to drinking once the agoraphobia symptoms become unmanageable. Treating the agoraphobia without addressing the alcohol use is less effective because the alcohol is interfering with both the medication response and the exposure work that is central to CBT. The integrated approach addresses the dynamic between the two conditions and produces substantially better outcomes.

Treatment of agoraphobia

Cognitive behavioural therapy (CBT) with structured exposure is the first-line treatment for agoraphobia and has strong evidence for both short-term and long-term effectiveness. CBT addresses the cognitive component (the catastrophic thinking about feared situations), the behavioural component (the avoidance), and the underlying anxiety response itself. Exposure therapy, a specific component of CBT, gradually exposes the patient to the feared situations starting with the least anxiety-provoking and working up to the most challenging. The repeated exposures, combined with anxiety-management skills, produce gradual extinction of the conditioned fear and revision of the catastrophic predictions.

Treatment typically runs for 12 to 20 sessions for an initial course, often with longer-term work for more entrenched presentations. The exposure work happens both in session and between sessions, with the patient practicing approach to feared situations in their own life. Many patients are initially reluctant to engage in exposure because the prospect is anxiety-provoking, but the work produces durable change when sustained. Newer variants of CBT including acceptance and commitment therapy (ACT) and mindfulness-based interventions are also useful for some patients.

Medications with evidence for agoraphobia include the SSRIs (sertraline, paroxetine, escitalopram, fluoxetine, citalopram, fluvoxamine), SNRIs (venlafaxine, duloxetine), and tricyclic antidepressants (clomipramine, imipramine). The medications are typically started at a low dose and titrated up over weeks to a therapeutic range. Response begins at 2 to 4 weeks of regular daily dosing and full response is typically reached at 6 to 8 weeks. Continuation for at least 12 months after response is generally recommended for anxiety disorders, with longer treatment for more severe or recurrent cases.

Benzodiazepines (lorazepam, clonazepam, alprazolam, diazepam) provide rapid acute anxiety relief and are sometimes used short-term during the early phase of treatment or for specific high-anxiety situations. The long-term use of benzodiazepines for agoraphobia is generally avoided because of dependence risk, tolerance development, interference with exposure-based therapy, and the dangerous combination with alcohol that many patients with agoraphobia also use. For patients on long-term benzodiazepines, a structured taper combined with active CBT and SSRI treatment is the typical approach.

Treatment of co-occurring conditions is essential. Alcohol use disorder requires medical detox if physical dependence is established, followed by integrated addiction treatment. Depression often responds to the same SSRIs and SNRIs used for the anxiety, with the therapy work addressing both conditions. Panic disorder responds well to CBT for panic combined with SSRI or SNRI treatment. Phuket Island Rehab provides residential addiction medicine treatment in Thailand with integrated care for co-occurring anxiety disorders including agoraphobia, panic disorder, and alcohol use disorder.

When anxiety and drinking have become more than occasional

For readers who recognise themselves in the agoraphobia description and who also drink regularly, the practical question is whether both patterns have crossed into clinical territory. The self-assessment earlier in this article addresses the agoraphobia component. For the alcohol use, NIAAA’s threshold of heavy drinking is more than 4 drinks per day or 14 per week for men, and more than 3 per day or 7 per week for women. Patterns that suggest alcohol use disorder include drinking more or longer than intended, unsuccessful efforts to cut down, drinking to manage anxiety, tolerance, withdrawal symptoms, and continued use despite consequences.

Treatment options when both conditions are present include outpatient therapy for the agoraphobia, often combined with outpatient or intensive outpatient care for the alcohol use disorder, with integrated assessment to understand how the two interact. For patients with more severe presentations including substantial functional impairment, established alcohol dependence with physical withdrawal, or recurrent panic attacks, residential treatment that addresses both conditions in an integrated way often produces better outcomes than sequential outpatient treatment.

Phuket Island Rehab provides residential addiction medicine treatment in Thailand with integrated care for co-occurring anxiety disorders including agoraphobia and panic disorder, alcohol use disorder, and the broader mental health work that supports recovery. The structured residential setting, the medical detox capability, the intensive therapy, and the time away from triggering environments give patients the space to do work on both conditions that is difficult to do in outpatient settings while continuing to live in the environment that maintained the patterns.

Summary

Agoraphobia is the anxiety disorder defined by fear of situations from which escape might be difficult or in which help might not be available if a panic attack or other distressing symptoms occurred. DSM-5 criteria require marked fear in at least two of five situational clusters: public transportation, open spaces, enclosed spaces, crowds or lines, and being outside the home alone. The fear must be persistent (6 months or more), cause substantial distress or functional impairment, and be out of proportion to the actual danger. A self-assessment with focused questions about avoidance of these situations can identify cases that warrant clinical evaluation. Symptoms include physical anxiety and panic features, cognitive catastrophic thinking, active avoidance, safety behaviours, and substantial functional impairment. Common contributors include genetic vulnerability, a history of panic attacks, stress and life events, and behavioural patterns that maintain the avoidance over years. First-line treatment is cognitive behavioural therapy with structured exposure, often combined with SSRI or SNRI medication. Heavy drinking is one of the most common ways people manage agoraphobia, and the alcohol use often becomes a clinical problem that complicates both conditions; integrated treatment is the standard of care for the combined presentation. As Dr. Ponlawat Pitsuwan summarises, “Agoraphobia is one of the more treatable anxiety disorders when properly diagnosed, but the diagnosis is often missed because patients present with the visible behaviours rather than with the underlying fear. The agoraphobic who has been managing for years with daily wine in the evenings has two conditions, not one, and addressing both together produces the change that addressing either alone never quite delivers.”

Frequently asked questions

What are the symptoms of agoraphobia?

Symptoms include marked fear or anxiety about at least two of five situational clusters (public transportation, open spaces, enclosed spaces, crowds or lines, being outside the home alone), persistent over 6 months, with active avoidance, safety behaviours, or distressed endurance of the situations, and substantial distress or functional impairment. Physical symptoms include the standard anxiety and panic features (racing heart, sweating, shortness of breath, dizziness). Behavioural symptoms include avoidance and safety behaviours. Cognitive symptoms include catastrophic thinking about the feared situations.

How is agoraphobia diagnosed?

Agoraphobia is diagnosed clinically by a mental health professional using the DSM-5 criteria. The diagnostic process includes a clinical interview, sometimes supplemented by standardised rating scales (the Agoraphobia subscale of the Anxiety Disorders Interview Schedule, the Mobility Inventory for Agoraphobia, the Panic Disorder Severity Scale). The clinician differentiates agoraphobia from related conditions including panic disorder, social anxiety disorder, generalised anxiety disorder, specific phobias, and post-traumatic stress disorder.

Is there an online agoraphobia test?

Several validated online tests for agoraphobia exist, including the Agoraphobic Cognitions Questionnaire, the Mobility Inventory for Agoraphobia, and the Panic and Agoraphobia Scale. These can support self-assessment and clinical evaluation but are not a substitute for formal clinical diagnosis. The structured self-assessment in this article maps directly to the DSM-5 criteria and can identify cases that warrant clinical evaluation. Online tests should not be used to self-diagnose or self-treat; if the screening suggests agoraphobia may be present, the next step is professional assessment.

Can agoraphobia be cured?

Agoraphobia can be substantially improved or fully resolved with appropriate treatment. CBT with structured exposure produces durable change in many patients, often within 12 to 20 sessions. Medications (SSRIs, SNRIs) provide additional benefit and are often combined with therapy. Many patients achieve sustained remission with continued maintenance treatment. The combination of consistent treatment and addressing co-occurring conditions including substance use produces the best outcomes.

What’s the difference between agoraphobia and panic disorder?

Panic disorder is defined by recurrent unexpected panic attacks plus persistent worry about additional attacks. Agoraphobia is defined by fear of situations where escape might be difficult or help unavailable. The two often co-occur; agoraphobia frequently develops after panic attacks as the person avoids situations where past attacks occurred. The DSM-5 separates the two conditions to clarify that agoraphobia can also exist without panic disorder. Treatment for the combined presentation addresses both the panic attacks and the avoidance pattern.

Why does alcohol make agoraphobia worse?

Alcohol provides short-term anxiety relief but worsens the underlying anxiety over the longer term through several mechanisms. Chronic heavy drinking produces compensatory changes in GABA-A and NMDA receptor function that elevate baseline anxiety when alcohol is not in the system. Alcohol withdrawal itself produces anxiety symptoms that can mimic the agoraphobia picture. Drinking interferes with the response to anxiety medications and with the exposure work central to CBT. The combined pattern of agoraphobia and alcohol use disorder is more challenging to treat than either alone and benefits from integrated care.

Sources

• American Psychiatric Association. DSM-5: Anxiety Disorders. https://www.psychiatry.org/psychiatrists/practice/dsm
• National Institute of Mental Health (NIMH). Agoraphobia. https://www.nimh.nih.gov/health/topics/anxiety-disorders
• National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults. https://www.nice.org.uk/guidance/cg113
• Anxiety and Depression Association of America. Agoraphobia. https://adaa.org/understanding-anxiety/panic-disorder-agoraphobia
• National Institute on Alcohol Abuse and Alcoholism (NIAAA). Anxiety and alcohol. NIAAA mental health and AUD
• World Health Organization. ICD-11: Mental, behavioural and neurodevelopmental disorders. https://icd.who.int/browse11

agoraphobia, agoraphobia test, agoraphobia self-assessment, agoraphobia screening, panic disorder, panic attack, panic, panic disorder with agoraphobia, anxiety disorder, generalised anxiety disorder, GAD, social anxiety disorder, social phobia, specific phobia, post-traumatic stress disorder, PTSD, obsessive-compulsive disorder, OCD, DSM-5, ICD-11, public transportation, open spaces, enclosed spaces, crowds, being outside the home alone, avoidance, safety behaviours, anticipatory anxiety, catastrophic thinking, derealisation, depersonalisation, panic attack symptoms, palpitations, sweating, trembling, shortness of breath, dizziness, nausea, fear of dying, fear of losing control, fear of fear, exposure therapy, in vivo exposure, imaginal exposure, cognitive behavioural therapy, CBT, acceptance and commitment therapy, ACT, mindfulness-based interventions, mindfulness, SSRI, SSRIs, sertraline, paroxetine, escitalopram, fluoxetine, citalopram, fluvoxamine, SNRI, venlafaxine, duloxetine, tricyclic antidepressant, TCA, clomipramine, imipramine, benzodiazepine, lorazepam, clonazepam, alprazolam, diazepam, beta-blocker, propranolol, alcohol, alcohol use disorder, AUD, heavy drinking, alcohol withdrawal, GABA-A receptor, NMDA receptor, glutamate, self-medication, dual diagnosis, co-occurring disorders, integrated treatment, Mobility Inventory for Agoraphobia, MIA, NIMH, NICE, APA, ADAA, NIAAA, WHO, Phuket Island Rehab.